These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17675819)

  • 21. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
    D'Haens G
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S209-16. PubMed ID: 20117344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New therapy in inflammatory bowel disease (infliximab)].
    Yoshizawa S; Hibi T
    Nihon Rinsho; 2008 Jul; 66(7):1279-85. PubMed ID: 18616118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
    Aardoom MA; Veereman G; de Ridder L
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetics and inflammatory bowel disease: progress and prospects.
    Ho GT; Lees C; Satsangi J
    Inflamm Bowel Dis; 2004 Mar; 10(2):148-58. PubMed ID: 15168816
    [No Abstract]   [Full Text] [Related]  

  • 25. Infliximab therapy in pediatric patients 7 years of age and younger.
    Kelsen JR; Grossman AB; Pauly-Hubbard H; Gupta K; Baldassano RN; Mamula P
    J Pediatr Gastroenterol Nutr; 2014 Dec; 59(6):758-62. PubMed ID: 25419596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guidelines for the management of inflammatory bowel disease in adults.
    Carter MJ; Lobo AJ; Travis SP;
    Gut; 2004 Sep; 53 Suppl 5(Suppl 5):V1-16. PubMed ID: 15306569
    [No Abstract]   [Full Text] [Related]  

  • 27. [Chronic inflammatory bowel diseases. Update on evidence-based therapy].
    MMW Fortschr Med; 2005 Apr; 147(17):58-9. PubMed ID: 15903063
    [No Abstract]   [Full Text] [Related]  

  • 28. [FAQs in chronic inflammatory bowel diseases. This way your patient stays in remission].
    Stiefelhagen P
    MMW Fortschr Med; 2011 Dec; 153(49-50):20-1. PubMed ID: 22308586
    [No Abstract]   [Full Text] [Related]  

  • 29. Listeria monocytogenes infection in patients with inflammatory bowel diseases receiving anti-tumor necrosis factor therapy.
    Ramos JM; García-Sepulcre MF; Masiá M; Brotons A; Grau MC; Gutiérrez F
    Rev Esp Enferm Dig; 2010 Oct; 102(10):614-6. PubMed ID: 21039077
    [No Abstract]   [Full Text] [Related]  

  • 30. [Current medical treatment of inflammatory bowel disease].
    Bosques-Padilla F
    Rev Gastroenterol Mex; 2007 Nov; 72 Suppl 2():92-101. PubMed ID: 18277494
    [No Abstract]   [Full Text] [Related]  

  • 31. Inflammatory bowel diseases: highlights from the United European Gastroenterology Week 2008.
    Kaser A; Tilg H
    Expert Opin Ther Targets; 2009 Feb; 13(2):259-63. PubMed ID: 19236243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review article: remission rates achievable by current therapies for inflammatory bowel disease.
    Peyrin-Biroulet L; Lémann M
    Aliment Pharmacol Ther; 2011 Apr; 33(8):870-9. PubMed ID: 21323689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variation in infliximab administration practices in the treatment of pediatric inflammatory bowel disease.
    Adler J; Sandberg KC; Shpeen BH; Eder SJ; Dhanani M; Clark SJ; Freed GL
    J Pediatr Gastroenterol Nutr; 2013 Jul; 57(1):35-8. PubMed ID: 23459317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of integrin antagonists in the treatment of inflammatory bowel disease.
    Beniwal-Patel P; Saha S
    Expert Opin Biol Ther; 2014 Dec; 14(12):1815-23. PubMed ID: 25288228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infliximab, azathioprine, or combination therapy for Crohn's disease.
    Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens G; Diamond RH; Broussard DL; Tang KL; van der Woude CJ; Rutgeerts P;
    N Engl J Med; 2010 Apr; 362(15):1383-95. PubMed ID: 20393175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease.
    Peng JC; Shen J; Ran ZH
    J Dig Dis; 2014 Nov; 15(11):585-90. PubMed ID: 25251263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can we alter the natural history of Crohn disease in children?
    Hyams JS; Markowitz JF
    J Pediatr Gastroenterol Nutr; 2005 Mar; 40(3):262-72. PubMed ID: 15735477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of chronic inflammatory bowel diseases].
    Lémann M
    Bull Acad Natl Med; 2007 Jun; 191(6):1125-41; discussion 1141. PubMed ID: 18402168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Corticosteroid refractory colonic Crohn disease with successful remission with infliximab].
    Alva E; Vásquez J; Frisancho O; Mantilla L; Yábar A; Morales D
    Rev Gastroenterol Peru; 2009; 29(1):51-4. PubMed ID: 19424409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Refractory inflammatory bowel disease in children.
    Oliva-Hemker M; Escher JC; Moore D; Dubinksy M; Hildebrand H; Koda YK; Murch S; Sandhu B; Seo JK; Tanzi MN; Warner B;
    J Pediatr Gastroenterol Nutr; 2008 Aug; 47(2):266-72. PubMed ID: 18664886
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.